ANDA 219989, held by Sandoz Inc. Carbidopa, Levodopa.
As of Nov 16, 2026, ANDA 219989 (Carbidopa And Levodopa), held by Sandoz Inc, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 12, 2025 | Original application | Tentative approval | None posted |
| Carbidopa And Levodopa140MG · capsule, extended release | Carbidopa, Levodopa | None (tentative approval) |
| Carbidopa And Levodopa87.5MG · capsule, extended release | Carbidopa, Levodopa | None (tentative approval) |
| Carbidopa And Levodopa350MG · capsule, extended release | Carbidopa, Levodopa | None (tentative approval) |
| Carbidopa And Levodopa70MG · capsule, extended release | Carbidopa, Levodopa | None (tentative approval) |
| Carbidopa And Levodopa280MG · capsule, extended release | Carbidopa, Levodopa | None (tentative approval) |
| Carbidopa And Levodopa52.5MG · capsule, extended release | Carbidopa, Levodopa | None (tentative approval) |
| Carbidopa And Levodopa210MG · capsule, extended release | Carbidopa, Levodopa | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters